Abstract BACKGROUND: For BRCA1/BRCA2 gene testing to benefit public health, mutation
carriers must initiate appropriate risk management strategies. There has been little research …

BACKGROUND. Women who are at increased risk for breast and ovarian cancers,
especially BRCA1 and BRCA2 mutation carriers, face a myriad of risk‐reduction options …

Background: Numerous studies have documented the short-term impact of BRCA1/BRCA2
(BRCA1/2) testing; however, little research has examined the long-term impact of testing. We …

Mutations in the BRCA1 gene are associated with an increased risk of breast and ovarian
cancer in carrier women. An understanding of behavioral responses to BRCA1 mutation …

Testing for mutations in BRCA1 and BRCA2 can provide important information about breast
and ovarian cancer risk to a small but identifiable subgroup of women. Women who test …

BACKGROUND: Testing for mutations in the breast and ovarian cancer susceptibility genes
BRCA1 and BRCA2 (BRCA) has been commercially available since 1996. PURPOSE: This …

Objective: Women who are carriers of BRCA gene mutations have an elevated lifetime risk
of developing breast or ovarian cancer. Although a number of risk-reducing options are …

Purpose: Despite the widespread availability of genetic testing for BRCA1/BRCA2
mutations, little is known about the impact of testing on ovarian cancer prevention and …

Background. Although genetic testing for breast cancer risk is clinically available, its impact
on health-related behaviors is unknown. This study examined prophylactic surgery and …

We conducted a prospective, observational study to determine breast cancer screening
practices among self-referred high-risk women who pursued genetic testing for BRCA1 and …